163 related articles for article (PubMed ID: 22093954)
1. Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseases.
Cosco D; Paolino D; Cilurzo F; Casale F; Fresta M
Int J Pharm; 2012 Jan; 422(1-2):229-37. PubMed ID: 22093954
[TBL] [Abstract][Full Text] [Related]
2. Effects of lipid composition and preparation conditions on physical-chemical properties, technological parameters and in vitro biological activity of gemcitabine-loaded liposomes.
Calvagno MG; Celia C; Paolino D; Cosco D; Iannone M; Castelli F; Doldo P; Frest M
Curr Drug Deliv; 2007 Jan; 4(1):89-101. PubMed ID: 17269921
[TBL] [Abstract][Full Text] [Related]
3. Peritoneal retention of liposomes: Effects of lipid composition, PEG coating and liposome charge.
Dadashzadeh S; Mirahmadi N; Babaei MH; Vali AM
J Control Release; 2010 Dec; 148(2):177-86. PubMed ID: 20800629
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine-loaded Folic Acid Tagged Liposomes: Improved Pharmacokinetic and Biodistribution Profile.
Unnam S; Panduragaiah VM; Sidramappa MA; Muddana Eswara BR
Curr Drug Deliv; 2019; 16(2):111-122. PubMed ID: 30360740
[TBL] [Abstract][Full Text] [Related]
5. Preparation of pH-sensitive, long-circulating and EGFR-targeted immunoliposomes.
Kim MJ; Lee HJ; Lee IA; Kim IY; Lim SK; Cho HA; Kim JS
Arch Pharm Res; 2008 Apr; 31(4):539-46. PubMed ID: 18449514
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel-loaded liposomes: The effect of lipid composition and purification on drug encapsulation and in vitro toxicity.
Pereira S; Egbu R; Jannati G; Al-Jamal WT
Int J Pharm; 2016 Nov; 514(1):150-159. PubMed ID: 27863659
[TBL] [Abstract][Full Text] [Related]
7. pH-sensitive stearoyl-PEG-poly(methacryloyl sulfadimethoxine) decorated liposomes for the delivery of gemcitabine to cancer cells.
Bersani S; Vila-Caballer M; Brazzale C; Barattin M; Salmaso S
Eur J Pharm Biopharm; 2014 Nov; 88(3):670-82. PubMed ID: 25157908
[TBL] [Abstract][Full Text] [Related]
8. Preparation, optimization and in vitro characterization of stearoyl-gemcitabine polymeric micelles: a comparison with its self-assembled nanoparticles.
Daman Z; Ostad S; Amini M; Gilani K
Int J Pharm; 2014 Jul; 468(1-2):142-51. PubMed ID: 24731731
[TBL] [Abstract][Full Text] [Related]
9. Development of high-content gemcitabine PEGylated liposomes and their cytotoxicity on drug-resistant pancreatic tumour cells.
Xu H; Paxton J; Lim J; Li Y; Zhang W; Duxfield L; Wu Z
Pharm Res; 2014 Oct; 31(10):2583-92. PubMed ID: 24639234
[TBL] [Abstract][Full Text] [Related]
10. Lyophilization of cholesterol-free PEGylated liposomes and its impact on drug loading by passive equilibration.
Chaudhury A; Das S; Lee RF; Tan KB; Ng WK; Tan RB; Chiu GN
Int J Pharm; 2012 Jul; 430(1-2):167-75. PubMed ID: 22537806
[TBL] [Abstract][Full Text] [Related]
11. Effective light-triggered contents release from helper lipid-incorporated liposomes co-encapsulating gemcitabine and a water-soluble photosensitizer.
Fuse T; Tagami T; Tane M; Ozeki T
Int J Pharm; 2018 Apr; 540(1-2):50-56. PubMed ID: 29410222
[TBL] [Abstract][Full Text] [Related]
12. Encapsulation of gemcitabine in RGD-modified nanoliposomes improves breast cancer inhibitory activity.
Cai W; Geng C; Jiang L; Sun J; Chen B; Zhou Y; Yang B; Lu H
Pharm Dev Technol; 2020 Jun; 25(5):640-648. PubMed ID: 32028816
[TBL] [Abstract][Full Text] [Related]
13. Surface-modified Epirubicin-HCl liposomes and its in vitro assessment in breast cancer cell-line: MCF-7.
Gandhi R; Khatri N; Baradia D; Vhora I; Misra A
Drug Deliv; 2016 May; 23(4):1152-62. PubMed ID: 25586675
[TBL] [Abstract][Full Text] [Related]
14. Assessment of a New Ginsenoside Rh2 Nanoniosomal Formulation for Enhanced Antitumor Efficacy on Prostate Cancer: An in vitro Study.
Zare-Zardini H; Alemi A; Taheri-Kafrani A; Hosseini SA; Soltaninejad H; Hamidieh AA; Haghi Karamallah M; Farrokhifar M; Farrokhifar M
Drug Des Devel Ther; 2020; 14():3315-3324. PubMed ID: 32884236
[TBL] [Abstract][Full Text] [Related]
15. Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance.
Bajelan E; Haeri A; Vali AM; Ostad SN; Dadashzadeh S
J Pharm Pharm Sci; 2012; 15(4):568-82. PubMed ID: 23106959
[TBL] [Abstract][Full Text] [Related]
16. Copper ion-mediated liposomal encapsulation of mitoxantrone: the role of anions in drug loading, retention and release.
Li C; Cui J; Li Y; Wang C; Li Y; Zhang L; Zhang L; Guo W; Wang J; Zhang H; Hao Y; Wang Y
Eur J Pharm Sci; 2008 Aug; 34(4-5):333-44. PubMed ID: 18573336
[TBL] [Abstract][Full Text] [Related]
17. Sterically stabilized liposomes incorporating the novel anticancer agent phospho-ibuprofen (MDC-917): preparation, characterization, and in vitro/in vivo evaluation.
Mattheolabakis G; Nie T; Constantinides PP; Rigas B
Pharm Res; 2012 Jun; 29(6):1435-43. PubMed ID: 22072052
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Lipid Types and Liposomal Formulations on Osteoblast Adiposity and Mineralization.
Chang SF; Yeh CC; Chen PJ; Chang HI
Molecules; 2018 Jan; 23(1):. PubMed ID: 29301300
[TBL] [Abstract][Full Text] [Related]
19. PEGylated liposomes modified with LHRH analogs for tumor targeting.
He Y; Zhang L; Song C
J Control Release; 2011 Nov; 152 Suppl 1():e29-31. PubMed ID: 22195906
[No Abstract] [Full Text] [Related]
20. PEG/RGD-modified magnetic polymeric liposomes for controlled drug release and tumor cell targeting.
Su W; Wang H; Wang S; Liao Z; Kang S; Peng Y; Han L; Chang J
Int J Pharm; 2012 Apr; 426(1-2):170-181. PubMed ID: 22266537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
